Our 3rd annual UK biopharma event tops this week — on Zoom — with José Baselga, top biotech CEOs and a look at the global financial scene
The first few years of Pascal Soriot’s reign as CEO of AstraZeneca were tough to watch, at times. Setbacks were more common than breakthroughs, and its inability to finish its new headquarters building in Cambridge, UK, seemed emblematic of its inner confusion. True, Soriot had inherited the worst pipeline in Big Pharma, but investors fretted for some time when the company would get back on track.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.